Anika Therapeutics Inc
NASDAQ:ANIK

Watchlist Manager
Anika Therapeutics Inc Logo
Anika Therapeutics Inc
NASDAQ:ANIK
Watchlist
Price: 16.28 USD -0.19%
Market Cap: 238.5m USD
Have any thoughts about
Anika Therapeutics Inc?
Write Note

Anika Therapeutics Inc
Stock-Based Compensation

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Anika Therapeutics Inc
Stock-Based Compensation Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Stock-Based Compensation CAGR 3Y CAGR 5Y CAGR 10Y
Anika Therapeutics Inc
NASDAQ:ANIK
Stock-Based Compensation
$14.7m
CAGR 3-Years
16%
CAGR 5-Years
23%
CAGR 10-Years
27%
Abbvie Inc
NYSE:ABBV
Stock-Based Compensation
$872m
CAGR 3-Years
8%
CAGR 5-Years
16%
CAGR 10-Years
14%
Gilead Sciences Inc
NASDAQ:GILD
Stock-Based Compensation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Stock-Based Compensation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Stock-Based Compensation
$739.3m
CAGR 3-Years
21%
CAGR 5-Years
16%
CAGR 10-Years
17%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Stock-Based Compensation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Anika Therapeutics Inc
Glance View

Market Cap
239.2m USD
Industry
Biotechnology

Anika Therapeutics, Inc. is an orthopedic and regenerative medicines company, which develops, manufactures and commercializes therapeutic products for pain management, tissue regeneration, and wound healing. The company is headquartered in Bedford, Massachusetts and currently employs 297 full-time employees. The firm is focused on developing, manufacturing, and commercializing products based on its hyaluronic acid (HA) technology platform. The Company’s product include OA Pain Management product consists of Monovisc and Orthovisc, which is single and multi-injection, HA-based viscosupplement product, Cingal, and Hyvisc; Joint Preservation and Restoration product consists of bone preserving joint technologies, soft tissue repair and regenerative solutions, and Non-Orthopedic product consists of Hyalobarrier, an anti-adhesion barrier indicated for use after abdomino-pelvic surgeries. Hyalomatrix is used for the treatment of wounds, such as burns, ulcers, ears, nose and throat disorders, and ophthalmic products.

ANIK Intrinsic Value
12.08 USD
Overvaluation 26%
Intrinsic Value
Price

See Also

What is Anika Therapeutics Inc's Stock-Based Compensation?
Stock-Based Compensation
14.7m USD

Based on the financial report for Sep 30, 2024, Anika Therapeutics Inc's Stock-Based Compensation amounts to 14.7m USD.

What is Anika Therapeutics Inc's Stock-Based Compensation growth rate?
Stock-Based Compensation CAGR 10Y
27%

Over the last year, the Stock-Based Compensation growth was -4%. The average annual Stock-Based Compensation growth rates for Anika Therapeutics Inc have been 16% over the past three years , 23% over the past five years , and 27% over the past ten years .

Back to Top